[1] |
Cacciaguerra L, Flanagan EP. Updates in NMOSD and MOGAD diagnosis and treatment: A tale of two central nervous system autoimmune inflammatory disorders[J]. Neurol Clin, 2024, 42(1):77-114.
doi: 10.1016/j.ncl.2023.06.009
pmid: 37980124
|
[2] |
Ambrosius W, Michalak S, Kozubski W, et al. Myelin oligodendrocyte glycoprotein antibody-associated disease: Current insights into the disease pathophysiology, diagnosis and management[J]. Int J Mol Sci, 2020, 22(1):100.
|
[3] |
Li Y, Liu X, Wang J, et al. Clinical features and imaging findings of myelin oligodendrocyte glycoprotein-igg-associated disorder (MOGAD)[J]. Front Aging Neurosci, 2022, 14:850743.
|
[4] |
Al-Ani A, Chen JJ, Costello F. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Current understanding and challenges[J]. J Neurol, 2023, 270(8):4132-4150.
doi: 10.1007/s00415-023-11737-8
pmid: 37154894
|
[5] |
Longbrake E. Myelin oligodendrocyte glycoprotein-associated disorders[J]. Continuum (Minneap Minn), 2022, 28(4):1171-1193.
doi: 10.1212/CON.0000000000001127
pmid: 35938661
|
[6] |
Marignier R, Hacohen Y, Cobo-Calvo A, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease[J]. Lancet Neurol, 2021, 20(9):762-772.
doi: 10.1016/S1474-4422(21)00218-0
pmid: 34418402
|
[7] |
Chen JJ, Flanagan EP, Jitprapaikulsan J, et al. Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and outcome[J]. Am J Ophthalmol, 2018, 195:8-15.
doi: S0002-9394(18)30401-X
pmid: 30055153
|
[8] |
Jitprapaikulsan J, Chen JJ, Flanagan EP, et al. Aquaporin-4 and myelin oligodendrocyte glycoprotein autoantibody status predict outcome of recurrent optic neuritis[J]. Ophthalmology, 2018, 125(10):1628-1637.
doi: S0161-6420(18)30240-9
pmid: 29716788
|
[9] |
Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria[J]. Lancet Neurol, 2023, 22(3):268-282.
doi: 10.1016/S1474-4422(22)00431-8
pmid: 36706773
|
[10] |
Jarius S, Kleiter I, Ruprecht K, et al. MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome[J]. J Neuroinflammation, 2016, 13(1):281.
|
[11] |
De Seze J. MOG-antibody neuromyelitis optica spectrum disorder: Is it a separate disease?[J]. Brain, 2017, 140(12):3072-3075.
doi: 10.1093/brain/awx292
pmid: 29194504
|
[12] |
Banks SA, Morris PP, Chen JJ, et al. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS[J]. J Neurol Neurosurg Psychiatry, 2020: jnnp-2020-325121.
|
[13] |
Valencia-Sanchez C, Guo Y, Krecke KN, et al. Cerebral cortical encephalitis in myelin oligodendrocyte glycoprotein antibody-associated disease[J]. Ann Neurol, 2023, 93(2):297-302.
|
[14] |
Shen CH, Zheng Y, Cai MT, et al. Seizure occurrence in myelin oligodendrocyte glycoprotein antibody-associated disease: A systematic review and meta-analysis[J]. Mult Scler Relat Disord, 2020, 42:102057.
|
[15] |
Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis[J]. Mult Scler, 2016, 22(4):470-482.
|
[16] |
Biotti D, Bonneville F, Tournaire E, et al. Optic neuritis in patients with anti-MOG antibodies spectrum disorder: MRI and clinical features from a large multicentric cohort in France[J]. J Neurol, 2017, 264(10):2173-2175.
doi: 10.1007/s00415-017-8615-8
pmid: 28914353
|
[17] |
Jarius S, Paul F, Aktas O, et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing[J]. J Neuroinflammation, 2018, 15(1):134.
|
[18] |
Dubey D, Pittock SJ, Krecke KN, et al. Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody[J]. JAMA Neurol, 2019, 76(3):301-309.
doi: 10.1001/jamaneurol.2018.4053
pmid: 30575890
|
[19] |
Cobo-Calvo A, Ruiz A, Maillart E, et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study[J]. Neurology, 2018, 90(21):e1858-e1869.
|
[20] |
Yang L, Li H, Xia W, et al. Quantitative brain lesion distribution may distinguish MOG-ab and AQP4-ab neuromyelitis optica spectrum disorders[J]. Eur Radiol, 2020, 30(3):1470-1479.
doi: 10.1007/s00330-019-06506-z
pmid: 31748853
|
[21] |
Ramanathan S, Mohammad S, Tantsis E, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination[J]. J Neurol Neurosurg Psychiatry, 2018, 89(2):127-137.
doi: 10.1136/jnnp-2017-316880
pmid: 29142145
|
[22] |
Santoro JD, Chitnis T. Diagnostic considerations in acute disseminated encephalomyelitis and the interface with MOG antibody[J]. Neuropediatrics, 2019, 50(5):273-279.
doi: 10.1055/s-0039-1693152
pmid: 31340401
|
[23] |
中华医学会神经病学分会神经感染性疾病与脑脊液细胞学学组. 中国自身免疫性脑炎诊治专家共识(2022年版)[J]. 中华神经科杂志, 2022, 55(9):931-949.
|
[24] |
Whittam DH, Karthikeayan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: Results of an international survey[J]. J Neurol, 2020, 267(12):3565-3577.
|
[25] |
Perez-Giraldo G, Caldito NG, Grebenciucova E. Transverse myelitis in myelin oligodendrocyte glycoprotein antibody-associated disease[J]. Front Neurol, 2023, 14:1210972.
|
[26] |
Jurynczyk M, Messina S, Woodhall MR, et al. Clinical presentation and prognosis in MOG-antibody disease: A UK study[J]. Brain, 2017, 140(12):3128-3138.
doi: 10.1093/brain/awx276
pmid: 29136091
|
[27] |
Hacohen Y, Wong YY, Lechner C, et al. Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease[J]. JAMA Neurol, 2018, 75(4):478-487.
doi: 10.1001/jamaneurol.2017.4601
pmid: 29305608
|
[28] |
Chang X, Zhang J, Li S, et al. Meta-analysis of the effectiveness of relapse prevention therapy for myelin-oligodendrocyte glycoprotein antibody-associated disease[J]. Mult Scler Relat Disord, 2023, 72:104571.
|
[29] |
Chen JJ, Huda S, Hacohen Y, et al. Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease[J]. JAMA Neurol, 2022, 79(5):518-525.
doi: 10.1001/jamaneurol.2022.0489
pmid: 35377395
|
[30] |
Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder[J]. Neurology, 2020, 95(2):e111-e120.
|
[31] |
Molazadeh N, Bilodeau PA, Salky R, et al. Predictors of relapsing disease course following index event in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)[J]. J Neurol Sci, 2024, 458:122909.
|